SYMBIOTEC · Healthcare · Drug Manufacturers - General
| Share price | ₹1,075.50 |
| P/E ratio | 62.7 |
| P/B ratio | 5.9 |
| ROE | 14.3% |
| ROCE | 14.3% |
| Book value | ₹183.27 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹869 Cr | ₹110 Cr | 21.2% |
| 2025 | ₹752 Cr | ₹97 Cr | 21.1% |
| 2024 | ₹716 Cr | ₹100 Cr | 18.5% |
| 2023 | ₹546 Cr | ₹23 Cr | 8.1% |
Symbiotec Pharma Lab Pvt. Ltd. develops, manufactures, and markets active pharmaceutical ingredients (APIs), with a primary focus on cortico-steroids and steroid-hormone APIs in both sterile and non-sterile forms. The company synthesizes progestin, estrone, testosterone, their derivatives, and anabolic steroids, supplying these in commercial volumes globally. It offers APIs and intermediate pharmaceutical products for therapeutic areas such as gastrointestinal ailments, cardiovascular disease, pain management, paediatrics, anti-infective, and dermatology. The company provides contract manufact